Balancing N-linked glycosylation to avoid disease.

Area of Science:

• Biochemistry
• Genetics
• Virology

Background:

• N-glycosylation is essential for cellular function, with complete loss being lethal.
• Deficiencies in N-glycosylation biosynthesis cause Congenital Disorders of Glycosylation (CDG) in humans, leading to diverse clinical symptoms.
• Specific genes like PMM2 and ALG6 harbor mutations linked to CDG, with some mutations occurring at high frequencies.

Purpose of the Study:

• To investigate the potential selective advantage of mutations compromising N-glycosylation.
• To explore the hypothesis that impaired glycosylation confers resistance to viral infections.
• To determine if reduced glycosylation is a risk factor or determinant in multi-genic diseases.

Main Methods:

• Analysis of mutation frequencies in genes involved in N-glycosylation pathways (e.g., PMM2, ALG6).
• Review of existing literature on CDG and viral interactions with host glycosylation.
• Assessment of N-glycosylation-compromising alleles in the context of multi-genic diseases.

Main Results:

• Certain mutations in N-glycosylation pathway genes, like PMM2 (R141H), are prevalent in specific populations.
• A potential mechanism for heterosis is proposed: misglycosylation of viral coat proteins inhibits infectivity without harming the host.
• This suggests a trade-off where reduced glycosylation provides viral resistance at the expense of CDG.

Conclusions:

• The maintenance of seemingly deleterious mutations in glycosylation genes may be driven by a selective advantage, such as enhanced resistance to viral infections.
• A balanced level of N-glycosylation might represent an evolutionary compromise between susceptibility to viral pathogens and the risk of CDG.
• Further research assessing these alleles in multi-genic diseases could clarify the role of impaired glycosylation in disease pathology.